Proteolysis-targeting chimeras (PROTACs) as an emerging drug discovery modality has
been extensively concerned in recent years. Over 20 years development, accumulated …

The ubiquitin-proteasome system (UPS) is the major machinery mediating specific protein
turnover in eukaryotic cells. By ubiquitylating unwanted, damaged, or harmful proteins and …

Posttranslational modifications (PTMs), such as phosphorylation, methylation, ubiquitination,
and acetylation, are important in governing protein expression levels. Proteolysis targeting …

Targeted protein degradation (TPD) is one of the key strategies of current targeted cancer
therapy, and it can eliminate some of the root causes of cancer, and effectively avoid drug …

Activating Nrf2 through inhibiting Keap1 has been proven to alleviate oxidative stress and
related diseases, including nonalcoholic fatty liver disease (NAFLD). Traditional Keap1 …

CDK9 plays a vital role in regulating RNA transcription and significantly impacts the
expression of short-lived proteins such as Mcl-1 and c-Myc. Thus, targeting CDK9 holds …

Introduction Target protein degradation (TPD) provides a novel therapeutic modality, other
than inhibition, through the direct depletion of target proteins. Two primary human protein …

Bone aging is characterized by an imbalance in the physiological and pathological
processes of osteogenesis, osteoclastogenesis, adipogenesis, and chondrogenesis …

Targeted proteasomal and autophagic protein degradation, often employing bifunctional
modalities, is a new paradigm for modulation of protein function. In an attempt to explore …

Covalent antibody recruiting molecules (cARMs) constitute a proximity-inducing chemical
strategy to modulate the recognition and elimination of cancer cells by the immune system …